explore -WSS

explore

author：leisure time 2025-09-27 16:23:14 - browse：2314

Adobe

At least 224 diabetes patients have been harmed by a software error causing their insulin pumps to spontaneously shut down, the Food and Drug Administration announced in a recall notice on Wednesday.

The product is made by Tandem Diabetes Care, which sells touchscreen insulin pumps and an accompanying app to help dose the medicine. Around 300,000 people use the technology. Tandem found that a bug in the app’s software is causing the app to repeatedly crash and relaunch, draining the insulin pump’s battery through unnecessary Bluetooth communication.

An insulin pump shutting down unexpectedly could kill people, especially if the shutdown occurs while the person is sleeping. There have been no reports of death so far, the FDA said. Tandem users commiserated over the issue on Reddit two months ago, with one user describing waking up at 2 a.m. to a dead pump. “Infuriating,” the user wrote. “Absolutely should be sending a notice out to all customers about this.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： FDA proposes changes to key medical devices approval pathway

hotspot

explore

WSS

Walmart eyes Medicare Advantage provider ChenMed

White House touts steps to stem shortages of cancer treatments

BioAge raises $170M for combination therapy with Zepbound

Acelyrin, a rare IPO success, stumbles in its first big test

Generate Biomedicines machine learning biotech raises $273M

Robert F. Kennedy is pitching centrism on health, even on abortion

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

Biden report: The neurospychology of memory and aging

Moonlake's readout produced a cash windfall. Risks remain

PhRMA lawsuit over Medicare drug price negotiation tossed

Apple is now the first public company to be valued at $3 trillion

FDA panel endorses Alnylam’s heart drug — after picking it apart

Medicare proposal to cover medical devices draws a mixed reaction

What to make of Biden’s latest efforts on cancer research

United colonoscopy coverage change 'may cost lives,' doctors say

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

New Covid vaccine is recommended for everyone 6 months or older

To avoid data mishandling cases, universities eye AI and other tools

Acelyrin, a rare IPO success, stumbles in its first big test

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

'Revelatory' study finds a smoking impact that remains after quitting

PEPFAR is under serious threat — and so is global health

hotspot

explore

entertainment

leisure time